Purpose: The mechanism of action and pharmacokinetics of sirolimus when used as part of a drug-eluting stent (DES) and the efficacy and cost of using DESs versus bare-metal stents are discussed.
Hosted on MSN9mon
Biodexa gains license for polyposis asset as stock more than doublesFyarro consists of sirolimus albumin-bound particles, and is administered as an intravenous (IV) infusion twice a month. The drug won US Food and Drug Administration (FDA) approval in 2021 for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback